Connect with us

Business

Pharmaceutical Firms Scale Back UK Investments Amid Drug Pricing Disputes

Published

on

Multinational drugmakers are pausing or pulling back investments in the United Kingdom, citing concerns over uncompetitive drug pricing and strained relations with the government. The slowdown comes as Britain seeks to position itself as a hub for life sciences, a sector the government has long promoted as central to its post-Brexit economic strategy.

Eli Lilly, AstraZeneca, and Merck are among the companies that have recently scaled back or halted projects in the UK. Earlier this month, AstraZeneca suspended a planned £200 million expansion of its Cambridge research site, following the cancellation of a vaccine project in Liverpool. Merck, known in Europe as MSD, said it would relocate its London research operations to the United States. Meanwhile, Eli Lilly has paused its £279 million London Gateway Lab, saying it was awaiting “more clarity around the UK life sciences environment.”

The moves follow sharp criticism from Eli Lilly’s chief executive Dave Ricks, who last week told the Financial Times that Britain was “probably the worst country in Europe” for drug pricing. His remarks have further highlighted growing friction between the pharmaceutical industry and the government.

Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), urged ministers to act. “We have a long and proud history of researching and manufacturing medicines in this country,” he said. “This is why we urge the government to improve how this country values and attracts future life sciences manufacturing.”

The UK spends a smaller share of its health budget on medicines than most developed nations — around 9% compared with 14–20% elsewhere. Much of this is due to the NHS’s heavy use of generic drugs and the role of the National Institute for Health and Care Excellence (NICE), which determines whether branded medicines are cost-effective. In addition, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) caps NHS spending on branded medicines, requiring firms to pay back revenue when expenditure exceeds agreed limits. Companies argue the rebates have become unsustainable.

See also  Wealth Taxes Survive in Only Three European Countries Amid Ongoing Debate

Adding to the pressure, new U.S. trade policies are reshaping the global market. President Donald Trump recently announced 100% tariffs on branded drug imports unless firms build plants in the U.S., alongside a “most favoured nation” pricing policy that could ripple across Europe. With the U.S. accounting for roughly 70% of global pharma profits, analysts say many companies are prioritising American operations over European ones.

Experts note that higher UK drug prices are not necessarily the solution. Irene Papanicolas, director at the Brown University School of Public Health, argued that if pharma firms retreat, “the bigger impact is on the economy and jobs” rather than patient access to medicines. Beth Woods, senior research fellow at the University of York, added: “Our research supports more stringent price regulation in the UK. More investment could fund screening programmes, hip replacements, or staffing increases.”

Analysts say that beyond pricing, the UK must strengthen its tax incentives, infrastructure, and research funding to remain attractive. Without decisive action, they warn, Britain risks losing ground in the global competition for pharmaceutical investment.

Business

Global Markets Rise as US–Iran Talks Ease Sentiment, but Oil and Geopolitical Risks Persist

Published

on

Global financial markets advanced on Friday as investors reacted cautiously to signs of progress in US–Iran negotiations, though ongoing disruption to shipping through the Strait of Hormuz and elevated oil prices kept risk sentiment fragile.

European equities opened higher across the board. The DAX gained 0.64%, supported by a 3.61% rise in Deutsche Post AG shares. France’s CAC 40 climbed 0.65%, led by a 3.43% jump in STMicroelectronics. In London, the FTSE 100 rose 0.38%, with gains in financial stocks including 3i Group, while the Euro Stoxx 50 added 0.88%.

Currency markets were relatively steady, with the euro trading at $1.161 and the British pound at $1.342 in early European trading. Sentiment was also lifted by better-than-expected economic data from Germany, where first-quarter growth came in at 0.4% year on year and consumer confidence improved heading into June, offering cautious optimism for Europe’s largest economy.

Asian markets followed the upward trend. Japan’s Nikkei 225 surged 2.7% to 63,339 after data showed inflation easing to a four-year low of 1.4% in April. Taiwan’s Taiex rose 2.2%, while Hong Kong’s Hang Seng and China’s Shanghai Composite each gained 0.9%. South Korea, Australia, and India also posted modest increases, reflecting broad regional strength.

Wall Street had earlier closed slightly higher. The S&P 500 added 0.2%, the Dow Jones rose 0.6%, and the Nasdaq edged up 0.1%. However, technology stocks showed mixed signals, with Nvidia falling 1.8% despite strong quarterly results, as investors weighed valuations against broader market uncertainty.

Oil markets remained the key source of volatility. Brent crude climbed 2.3% to $104.97 a barrel, while US West Texas Intermediate rose 1.8% to $98.10. Prices remain significantly above pre-conflict levels, driven by continued disruption in the Strait of Hormuz, through which roughly a quarter of global seaborne oil flows pass.

See also  Azerbaijan’s SOFAZ fund gains from rising gold prices amid global market uncertainty

Shipping through the strategic waterway remains constrained, with limited signs of recovery as diplomatic negotiations continue without resolution. Analysts say markets are highly sensitive to developments in talks between Washington and Tehran, with ING commodities strategists noting that optimism exists but uncertainty dominates trading conditions.

Geopolitical tensions also weighed on policy discussions in Washington, where a planned congressional vote on war powers legislation was postponed amid insufficient support.

In bond markets, US Treasury yields eased slightly to 4.57% after earlier spikes driven by inflation concerns linked to energy prices. The movement reflected ongoing caution among investors balancing growth expectations with persistent geopolitical risk.

Corporate earnings added a bright spot in Asia, where Lenovo Group surged more than 20% after reporting stronger-than-expected quarterly revenue of $21.6 billion, driven by robust performance in its PC and smart devices division.

Continue Reading

Business

Goldman Sachs tapped to lead SpaceX IPO as Musk eyes record-breaking market debut

Published

on

Goldman Sachs has reportedly secured the lead underwriting role for the anticipated stock market debut of SpaceX, a move that signals preparations are accelerating for what could become the largest initial public offering in history.

According to sources cited by CNBC, the aerospace and artificial intelligence company founded by Elon Musk is expected to move ahead with a public listing later this year at a valuation of at least $1.25 trillion.

Such a valuation would place SpaceX among the world’s most valuable publicly traded companies immediately after listing, potentially ranking ahead of Tesla, another company led by Musk.

The planned flotation is also expected to further boost Musk’s personal fortune and could make him the first person to reach trillionaire status, according to market analysts.

Reports suggest the company is considering an unusual structure for the offering that would reserve a significant portion of shares for individual investors. SpaceX is said to be exploring plans to allocate as much as 30 percent of IPO shares to retail buyers, a move that would give smaller investors broader access to one of the most highly anticipated stock offerings in recent years.

Large technology IPOs are typically dominated by institutional investors such as hedge funds and pension firms, making the proposed retail allocation notable within the investment industry.

Analysts said much of SpaceX’s valuation growth has been driven by its satellite internet business, Starlink, which has rapidly expanded its global subscriber base and established a recurring revenue stream.

The company also increased its exposure to artificial intelligence earlier this year through an all-stock deal involving xAI, another Musk-controlled business. The transaction reportedly valued SpaceX at $1 trillion and xAI at $250 billion, creating a combined private valuation of $1.25 trillion.

See also  Commerzbank Delivers Strongest Quarterly Results in Over a Decade Amid Takeover Tensions

The expected listing comes at a time when global IPO markets are beginning to recover after several years of weak activity caused by higher interest rates and volatility in technology stocks.

Recent enthusiasm around AI-related firms has revived investor appetite for major public offerings. Last week, AI chipmaker Cerebras Systems debuted on the Nasdaq and ended trading with a valuation near $95 billion, strengthening expectations for more large-scale technology listings in 2026.

For Goldman Sachs, landing the lead role in the SpaceX offering would represent one of the most prestigious deals in modern Wall Street history. Competition among major investment banks for high-profile technology listings has intensified as firms seek to secure lucrative underwriting fees and strengthen relationships with fast-growing AI and technology companies.

Neither SpaceX nor Goldman Sachs has publicly confirmed the reports.

Continue Reading

Business

Greek Stocks Stage Remarkable Comeback After Years of Financial Turmoil

Published

on

A decade after Greece’s financial crisis pushed its banking system to the brink and wiped out most of the country’s stock market value, Athens has emerged as one of the world’s strongest-performing equity markets, outperforming major global indices including the Nasdaq 100 over the past five years.

The recovery marks a dramatic reversal for a country once viewed as the eurozone’s biggest financial risk. In 2015, Greece imposed capital controls, shut its banks and froze trading on the Athens Stock Exchange as fears of sovereign default shook global markets. At the height of the crisis, cash withdrawals were limited to €60 a day and Greek government debt had been downgraded to junk status by major ratings agencies.

By February 2016, the Athens Composite Index had fallen more than 90 percent from its 2007 peak, while Greek banking shares lost nearly all their value.

Today, the picture looks very different.

The Athens Composite Index has returned about 146 percent over the past five years on a total-return basis, outpacing the Nasdaq 100, which gained around 116 percent during the same period. Greece’s rebound has been driven by sweeping banking reforms, stronger public finances and renewed investor confidence.

Greek banks played a central role in the recovery. Lenders including National Bank of Greece, Eurobank, Piraeus Bank and Alpha Bank spent years dealing with enormous volumes of bad loans accumulated during the debt crisis. At one point, nearly half of all loans on their books were classified as non-performing.

The clean-up accelerated under the government-backed Hercules asset protection scheme, which allowed banks to remove billions of euros in troubled loans from their balance sheets. Improved profitability, stronger deposits and tighter cost controls followed.

See also  German Court Rules Christmas Decorations Can Be Sold on Sundays in NRW Garden Centres

By 2025, the country’s four biggest banks had collectively posted profits close to €5 billion, with several restoring shareholder payouts and share buybacks.

At the same time, Greece carried out major tax and fiscal reforms under international supervision. Digital tax collection systems boosted compliance rates, while government finances steadily improved. Greece recorded primary budget surpluses in both 2024 and 2025, helping reduce its debt burden sharply from pandemic-era highs.

The recovery also prompted credit rating agencies to restore Greece to investment-grade status for the first time in more than a decade. Moody’s became the last major agency to do so in 2025.

International investors have increasingly returned to Greek assets, encouraged by still-attractive valuations compared with other European markets. Shares in some Greek banks have risen roughly 500 percent over the last five years, though many still trade at lower earnings multiples than their European peers.

Athens also received a major boost after Euronext completed its acquisition of the Greek stock exchange in late 2025, increasing the visibility of Greek companies among international investors and index funds.

Despite the turnaround, challenges remain. Greece’s economy is still heavily reliant on tourism, inflation remains elevated and officials warn that tensions in the Middle East could affect growth and energy prices.

Even so, Greece’s transformation from financial crisis symbol to one of Europe’s strongest market recoveries has become one of the most notable turnaround stories in global finance.

Continue Reading

Trending